{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:40:47Z","timestamp":1784263247075,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The atypical Parkinsonian disorder progressive supranuclear palsy (PSP) forms a diagnostic challenge, resulting in frequent misdiagnosis and delay in treatment. Although structural MRI can detect PSP signs at more advanced stages, emerging diagnostic tools such as tau-PET and quantitative susceptibility mapping (QSM) may allow for earlier detection. This exploratory study aimed to investigate differences in QSM data of patients with PSP and healthy controls (HCs) and for the first time assess possible correlations between QSM and tau-PET data in patients with PSP to explore the relationship between tau aggregation and iron susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively investigated differences in susceptibility values of brain structures, as assessed by QSM, between 11 HCs and 31 patients with PSP [Richardson\u2019s syndrome (PSP-RS):\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      14; other subtypes (PSP-nonRS):\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      17]. Additionally, we examined co-registered [\n                      <jats:sup>18<\/jats:sup>\n                      F]PI-2620\u00a0PET and QSM data in the 31 patients with PSP to explore the relationship between tau accumulation and susceptibility changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to HCs, patients with PSP showed higher QSM values in left nucleus caudate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and bilateral dentate nucleus (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Patients with the subtype PSP-RS showed higher QSM values than HCs in left dentate nucleus (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). The association between the patients\u2019 QSM and tau-PET data showed a significant positive correlation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest distinct patterns of regional iron accumulation in patients with PSP and its subtypes and support an association between iron and tau pathology. The data encourage further investigation in longitudinal studies and validation in larger cohorts to examine the value of QSM as a possible diagnostic biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07600-9","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:09:45Z","timestamp":1761955785000},"page":"2099-2109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hybrid Tau-PET\/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET"],"prefix":"10.1007","volume":"53","author":[{"given":"Fiona","family":"Weih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-9432","authenticated-orcid":false,"given":"Michael","family":"Rullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Henssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thies","family":"Jochimsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schildan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost-Julian","family":"Rumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias L.","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-8334","authenticated-orcid":false,"given":"Solveig","family":"Tiepolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"7600_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70042-0","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges [eng]. Lancet Neurol. 2009. https:\/\/doi.org\/10.1016\/S1474-4422(09)70042-0.","journal-title":"Lancet Neurol"},{"key":"7600_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12091126","author":"Y Barer","year":"2022","unstructured":"Barer Y, Chodick G, Cohen R, Grabarnik-John M, Ye X, Zamudio J, et al. Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in Israel [eng]. Brain Sci. 2022. https:\/\/doi.org\/10.3390\/brainsci12091126.","journal-title":"Brain Sci"},{"key":"7600_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1964.00460160003001","author":"JC Steele","year":"1964","unstructured":"Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia [eng]. Arch Neurol. 1964. https:\/\/doi.org\/10.1001\/archneur.1964.00460160003001.","journal-title":"Arch Neurol"},{"key":"7600_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.09.041","author":"G Respondek","year":"2016","unstructured":"Respondek G, H\u00f6glinger GU. The phenotypic spectrum of progressive supranuclear palsy [eng]. Parkinsonism Relat Disord. 2016. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.041.","journal-title":"Parkinsonism Relat Disord"},{"key":"7600_CR5","doi-asserted-by":"publisher","DOI":"10.1148\/rg.345140009","author":"SM Broski","year":"2014","unstructured":"Broski SM, Hunt CH, Johnson GB, Morreale RF, Lowe VJ, Peller PJ. Structural and functional imaging in parkinsonian syndromes [eng]. Radiographics. 2014. https:\/\/doi.org\/10.1148\/rg.345140009.","journal-title":"Radiographics"},{"key":"7600_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101722","author":"F Albrecht","year":"2019","unstructured":"Albrecht F, Bisenius S, Neumann J, Whitwell J, Schroeter ML. Atrophy in midbrain & cerebral\/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis [eng]. Neuroimage Clin. 2019. https:\/\/doi.org\/10.1016\/j.nicl.2019.101722.","journal-title":"Neuroimage Clin"},{"key":"7600_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12613","author":"S Bacchi","year":"2018","unstructured":"Bacchi S, Chim I, Patel S. Specificity and sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy [eng]. J Med Imaging Radiat Oncol. 2018. https:\/\/doi.org\/10.1111\/1754-9485.12613.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"7600_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2526","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy [eng]. JAMA Neurol. 2020. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526.","journal-title":"JAMA Neurol"},{"key":"7600_CR9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262854","author":"K Messerschmidt","year":"2022","unstructured":"Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann K-T, Rauchmann B-S, et al. 18F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy [eng]. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.121.262854.","journal-title":"J Nucl Med"},{"key":"7600_CR10","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2015.00136","author":"C Liu","year":"2015","unstructured":"Liu C, Wei H, Gong N-J, Cronin M, Dibb R, Decker K. Quantitative susceptibility mapping: contrast mechanisms and clinical applications [eng]. Tomography. 2015. https:\/\/doi.org\/10.18383\/j.tom.2015.00136.","journal-title":"Tomography"},{"key":"7600_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.25358","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu T. Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker [eng]. Magn Reson Med. 2015. https:\/\/doi.org\/10.1002\/mrm.25358.","journal-title":"Magn Reson Med"},{"key":"7600_CR12","doi-asserted-by":"publisher","DOI":"10.3233\/jad-220002","author":"R Pan","year":"2022","unstructured":"Pan R, Luo S, Huang Q, Li W, Cai T, Lai K, et al. The associations of cerebrospinal fluid ferritin with neurodegeneration and neuroinflammation along the Alzheimer\u2019s disease continuum [eng]. J Alzheimers Dis. 2022. https:\/\/doi.org\/10.3233\/jad-220002.","journal-title":"J Alzheimers Dis"},{"key":"7600_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29613","author":"R Satoh","year":"2023","unstructured":"Satoh R, Weigand SD, Pham NTT, Ali F, Arani A, Senjem ML, et al. Magnetic susceptibility in progressive supranuclear palsy variants, Parkinson\u2019s disease, and corticobasal syndrome [eng]. Mov Disord. 2023. https:\/\/doi.org\/10.1002\/mds.29613.","journal-title":"Mov Disord"},{"key":"7600_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.08.029","author":"H Sj\u00f6str\u00f6m","year":"2017","unstructured":"Sj\u00f6str\u00f6m H, Granberg T, Westman E, Svenningsson P. Quantitative susceptibility mapping differentiates between parkinsonian disorders [eng]. Parkinsonism Relat Disord. 2017. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.08.029.","journal-title":"Parkinsonism Relat Disord"},{"key":"7600_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003167","author":"J Jin","year":"2024","unstructured":"Jin J, Su D, Zhang J, Lam JST, Zhou J, Feng T. Iron deposition in subcortical nuclei of Parkinson\u2019s disease: a meta-analysis of quantitative iron-sensitive magnetic resonance imaging studies [eng]. Chin Med J (Engl). 2024. https:\/\/doi.org\/10.1097\/CM9.0000000000003167.","journal-title":"Chin Med J (Engl)"},{"key":"7600_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-39","author":"KK Tha","year":"2012","unstructured":"Tha KK, Terae S, Tsukahara A, Soma H, Morita R, Yabe I, et al. Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy [eng]. BMC Neurol. 2012. https:\/\/doi.org\/10.1186\/1471-2377-12-39.","journal-title":"BMC Neurol"},{"key":"7600_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109243","author":"S Tiepolt","year":"2020","unstructured":"Tiepolt S, Rullmann M, Jochimsen TH, Gertz H-J, Schroeter ML, Patt M, et al. Quantitative susceptibility mapping in \u03b2-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET\/MRI study [eng]. Eur J Radiol. 2020. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109243.","journal-title":"Eur J Radiol"},{"key":"7600_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030458","author":"M Rullmann","year":"2022","unstructured":"Rullmann M, Brendel M, Schroeter ML, Saur D, Levin J, Perneczky RG, et al. Multicenter 18F-PI-2620 PET for in vivo braak staging of Tau pathology in Alzheimer\u2019s disease [eng]. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12030458.","journal-title":"Biomolecules"},{"key":"7600_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/01.WCB.0000085441.37552.CA","author":"M Ichise","year":"2003","unstructured":"Ichise M, Liow J-S, Lu J-Q, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to 11CDASB positron emission tomography studies of the serotonin transporter in human brain [eng]. J Cereb Blood Flow Metab. 2003. https:\/\/doi.org\/10.1097\/01.WCB.0000085441.37552.CA.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7600_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.10.002","author":"JP Marques","year":"2010","unstructured":"Marques JP, Kober T, Krueger G, van der Zwaag W, van de Moortele P-F, Gruetter R. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field [eng]. Neuroimage. 2010. https:\/\/doi.org\/10.1016\/j.neuroimage.2009.10.002.","journal-title":"Neuroimage"},{"key":"7600_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.26946","author":"Z Liu","year":"2018","unstructured":"Liu Z, Spincemaille P, Yao Y, Zhang Y, Wang Y. MEDI+0: Morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping [eng]. Magn Reson Med. 2018. https:\/\/doi.org\/10.1002\/mrm.26946.","journal-title":"Magn Reson Med"},{"key":"7600_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12658","author":"P Spincemaille","year":"2019","unstructured":"Spincemaille P, Liu Z, Zhang S, Kovanlikaya I, Ippoliti M, Makowski M, et al. Clinical integration of automated processing for brain quantitative susceptibility mapping: multi-site reproducibility and single-site robustness [eng]. J Neuroimaging. 2019. https:\/\/doi.org\/10.1111\/jon.12658.","journal-title":"J Neuroimaging"},{"key":"7600_CR23","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.0978","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain [eng]. Neuroimage. 2002. https:\/\/doi.org\/10.1006\/nimg.2001.0978.","journal-title":"Neuroimage"},{"key":"7600_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2015.07.028","author":"MC Keuken","year":"2015","unstructured":"Keuken MC, Forstmann BU. A probabilistic atlas of the basal ganglia using 7 T MRI [eng]. Data Brief. 2015. https:\/\/doi.org\/10.1016\/j.dib.2015.07.028.","journal-title":"Data Brief"},{"key":"7600_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.01.045","author":"J Diedrichsen","year":"2009","unstructured":"Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N. A probabilistic MR atlas of the human cerebellum [eng]. Neuroimage. 2009. https:\/\/doi.org\/10.1016\/j.neuroimage.2009.01.045.","journal-title":"Neuroimage"},{"key":"7600_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02158-2","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns of tau pathology in progressive supranuclear palsy [eng]. Acta Neuropathol. 2020. https:\/\/doi.org\/10.1007\/s00401-020-02158-2.","journal-title":"Acta Neuropathol"},{"key":"7600_CR27","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"key":"7600_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116443","author":"M Azuma","year":"2019","unstructured":"Azuma M, Hirai T, Nakaura T, Kitajima M, Yamashita S, Hashimoto M, et al. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson\u2019s disease [eng]. J Neurol Sci. 2019. https:\/\/doi.org\/10.1016\/j.jns.2019.116443.","journal-title":"J Neurol Sci"},{"key":"7600_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-023-02352-5","author":"S Krishnan","year":"2024","unstructured":"Krishnan S, George SS, Radhakrishnan V, Raghavan S, Thomas B, Thulaseedharan JV, et al. Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy [eng]. Acta Neurol Belg. 2024. https:\/\/doi.org\/10.1007\/s13760-023-02352-5.","journal-title":"Acta Neurol Belg"},{"key":"7600_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.11.009","author":"Y-H Han","year":"2013","unstructured":"Han Y-H, Lee J-H, Kang B-M, Mun C-W, Baik S-K, Shin Y-I, et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy [eng]. J Neurol Sci. 2013. https:\/\/doi.org\/10.1016\/j.jns.2012.11.009.","journal-title":"J Neurol Sci"},{"key":"7600_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42565-4","author":"H Sj\u00f6str\u00f6m","year":"2019","unstructured":"Sj\u00f6str\u00f6m H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, et al. Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism [eng]. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-019-42565-4.","journal-title":"Sci Rep"},{"key":"7600_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00276","author":"SS Rao","year":"2018","unstructured":"Rao SS, Adlard PA. Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration [eng]. Front Mol Neurosci. 2018. https:\/\/doi.org\/10.3389\/fnmol.2018.00276.","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"7600_CR33","first-page":"1531","volume":"152","author":"M P\u00e9rez","year":"1998","unstructured":"P\u00e9rez M, Valpuesta JM, de Garcini EM, Quintana C, Arrasate M, L\u00f3pez Carrascosa JL, et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy [eng]. Am J Pathol. 1998;152(6):1531\u20139.","journal-title":"Am J Pathol"},{"key":"7600_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29311","author":"EW Wang","year":"2023","unstructured":"Wang EW, Brown GL, Lewis MM, Jellen LC, Pu C, Johnson ML, et al. Susceptibility magnetic resonance imaging correlates with glial density and tau in the Substantia Nigra Pars Compacta [eng]. Mov Disord. 2023. https:\/\/doi.org\/10.1002\/mds.29311.","journal-title":"Mov Disord"},{"key":"7600_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04397-2","author":"H Kroth","year":"2019","unstructured":"Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of 18FPI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies [eng]. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04397-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7600_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-05919-x","author":"M Picillo","year":"2022","unstructured":"Picillo M, Tepedino MF, Abate F, Ponticorvo S, Erro R, Cuoco S, et al. Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson\u2019s syndrome [eng]. Neurol Sci. 2022. https:\/\/doi.org\/10.1007\/s10072-022-05919-x.","journal-title":"Neurol Sci"},{"key":"7600_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2003.00529.x","author":"Y Motoi","year":"2004","unstructured":"Motoi Y, Takanashi M, Itaya M, Ikeda K, Mizuno Y, Mori H. Glial localization of four-repeat tau in atypical progressive supranuclear palsy [eng]. Neuropathology. 2004. https:\/\/doi.org\/10.1111\/j.1440-1789.2003.00529.x.","journal-title":"Neuropathology"},{"key":"7600_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.05.049","author":"C Langkammer","year":"2012","unstructured":"Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study [eng]. Neuroimage. 2012. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.05.049.","journal-title":"Neuroimage"},{"key":"7600_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162460","author":"C Langkammer","year":"2016","unstructured":"Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, et al. Quantitative susceptibility mapping in Parkinson\u2019s disease [eng]. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0162460.","journal-title":"PLoS ONE"},{"key":"7600_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.618435","author":"P Ravanfar","year":"2021","unstructured":"Ravanfar P, Loi SM, Syeda WT, van Rheenen TE, Bush AI, Desmond P, et al. Systematic review: quantitative susceptibility mapping (QSM) of brain iron profile in neurodegenerative diseases [eng]. Front Neurosci. 2021. https:\/\/doi.org\/10.3389\/fnins.2021.618435.","journal-title":"Front Neurosci"},{"key":"7600_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-010-0677-6","author":"D Gupta","year":"2010","unstructured":"Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson\u2019s disease and atypical parkinsonism [eng]. Neuroradiology. 2010. https:\/\/doi.org\/10.1007\/s00234-010-0677-6.","journal-title":"Neuroradiology"},{"key":"7600_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-019-0507-7","author":"A Reinert","year":"2019","unstructured":"Reinert A, Morawski M, Seeger J, Arendt T, Reinert T. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations [eng]. BMC Neurosci. 2019. https:\/\/doi.org\/10.1186\/s12868-019-0507-7.","journal-title":"BMC Neurosci"},{"key":"7600_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy [eng]. Brain. 2007. https:\/\/doi.org\/10.1093\/brain\/awm032.","journal-title":"Brain"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07600-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:03Z","timestamp":1769834583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7600"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07600-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of LMU Munich (application numbers 17\u2013569 and 19\u2013022). Clinical trial number not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MB is a member of the Neuroimaging Committee of the EANM. MB has received speaker honoraria from Roche, GE Healthcare, and Life Molecular Imaging; has advised Life Molecular Imaging; and is currently on the advisory board of MIAC. All the other authors declare that no conflicts of interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}